Conjugated Monoclonal Antibodies Global Market Report 2024

The conjugated monoclonal antibodies market size has grown strongly in recent years. It will grow from $10.9 billion in 2023 to $11.48 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth observed in the historical period owes its momentum to several key factors. These include the rising incidence of cancer cases, the expansion of the private healthcare sector providing specialized treatments, governmental support initiatives, and the overall increase in the patient population seeking advanced medical care. These factors collectively contributed to the growth and development of therapies involving conjugated monoclonal antibodies during that time.

The conjugated monoclonal antibodies market size is expected to see strongly grown in the next few years. It will grow to $14.64 billion in 2028 at a compound annual growth rate (CAGR) of 6.3%. The anticipated growth in the forecast period is expected to be driven by several significant factors. These include improved accessibility to healthcare services, heightened demand for minimally invasive medical procedures, the exploration of immunotherapeutic combinations, expanded healthcare accessibility, and the broadening of indications for treatments.

The rising popularity and therapeutic potential of conjugated monoclonal antibodies, specifically antibody-drug conjugates (ADCs), are projected to fuel demand within the market. ADCs, comprising monoclonal antibodies coupled with potent cytotoxic drugs through linkers to target antigen-expressing tumor cells, are primarily employed in cancer treatment. Despite the U.S. Food and Drug Administration approving only three ADCs in the past few years, the correlation between increased approvals and the application of conjugated monoclonal antibodies, particularly in cancer treatment, substantiates the market's growth trajectory.

The prevalence of cancer is anticipated to be a driving force behind the expansion of the conjugated monoclonal antibodies market. With cancer characterized by uncontrolled abnormal cell growth forming tumors, the targeted and precise mechanism of action offered by these antibodies significantly enhances the quality of life for patients. Macmillan Cancer Support estimates a progressive rise in cancer cases, from 3 million in 2020 to a projected 5.3 million by 2040. This substantial cancer prevalence is a key driver fueling growth in the market for conjugated monoclonal antibodies. Leading firms operating in the realm of conjugated monoclonal antibodies are leveraging strategic partnerships to bolster their capabilities and offer comprehensive solutions. These partnerships entail companies leveraging each other's strengths and resources for mutual success. For example, in July 2023, BeiGene Ltd., a U.S.-based biotech firm, joined forces with Duality Biologics, a China-based clinical stage company, aiming to develop and commercialize a preclinical antibody-drug conjugate (ADC) therapy targeting specific solid tumors. The combined strengths of both entities are poised to expedite the development and market entry of this promising ADC therapy.

In June 2023 was indeed aimed at bolstering Lonza's capabilities in the development and manufacturing of antibody-drug conjugates (ADCs). The acquisition was focused on enhancing Lonza's ADC portfolio and gaining access to Synaffix's pipeline of ADC candidates. The specific financial details of the acquisition were not disclosed.

Major companies operating in the conjugated monoclonal antibodies market include Pfizer Inc., F. Hoffmann-La Roche AG, Bristol -Myers Squibb, Merck & Co. Inc., Immunomedics Inc., Takeda Pharmaceuticals Industries Ltd., Daiichi Sankyo Company Limited, Actinium Pharmaceutical, Nordic Nanovector Inc., Spectrum Pharmaceuticals Inc., AbbVie Inc., Bayer AG, AstraZeneca PLC, Novartis AG, Amgen, Celgene, Genentech, Emergent BioSolutions, Genzyme, Incyte Corporation, Kite Pharma, MorphoSys AG, Regeneron Pharmaceuticals, Seattle Genetics.

North America was the largest region in the conjugated monoclonal antibody market in 2023. The Middle East is expected to be the fastest growing region in the global conjugated monoclonal antibodies market share during the forecast period. The regions covered in the conjugated monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the conjugated monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada. The conjugated monoclonal antibodies market consists of sales of Brentuximab vedotin and Ado-trastuzumab emtansine. Values in this market are 'factory gate values,' that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The primary drugs categorized as conjugated monoclonal antibodies are Adcetris and Kadcyla. Adcetris, a brand-name medication, is designed to treat specific forms of lymphoma in adults. Lymphoma is a type of cancer affecting the lymphatic system and lymphocytes, a type of white blood cell. These therapies utilize various technologies, including cleavable and non-cleavable linkers, and find application in treating conditions such as blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumors, and other malignancies.

The conjugated monoclonal antibodies market research report is one of a series of new reports provides conjugated monoclonal antibodies market statistics, including industry global market size, regional shares, competitors with a conjugated monoclonal antibodies market share, detailed conjugated monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the conjugated monoclonal antibodies industry. The conjugated monoclonal antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 1-3 business days.